Toxicity Testing Moves from the Legislature to the Petri Dish—and Back  by Gura, Trisha
Leading Edge
AnalysisToxicity Testing Moves from the Legislature 
to the Petri Dish—and Back
With the growing cost of using animals to test the safety of new chemicals and an increasing 
backlog of chemicals awaiting testing, the quest for cell-based in vitro alternatives for toxicity 
testing is gaining momentum.When a transformation takes place in a 
field of science, rarely is the cause sin-
gular. Such is true in toxicology, where 
a constellation of regulatory, scientific, 
and public/social changes are com-
ing together to spearhead a real shift in 
practice. Animals, principally rodents, 
have long been the mainstay for testing 
the toxicity of commercial chemicals, 
pesticides, pharmaceuticals, and other 
substances. Since the 1920s, animals 
have been used to test the safety of new 
chemicals (including those in cosmetics) 
as well as drugs and vaccines. But now 
a “sea change” is taking place as a high-
level initiative in the US and powerful 
new legislation in Europe are pushing in 
vitro alternatives to the foreground.
“Toxicology is becoming a real sci-
ence,” says Alan Goldberg, director of the 
Center for Alternatives to Animal Testing 
at Johns Hopkins University in Baltimore, 
MD. “It is moving from largely an obser-
vational enterprise to a science based 
on biological pathways, cellular mecha-
nisms, and the chemical understanding 
of molecular systems.” Such advance-
ment has its roots in pragmatism. Offi-
cials at the National Toxicology Program 
(NTP) and the Environmental Protection 
Agency (EPA) are facing an intractable 
problem. They have to assure the safety 
of at least 2000 new compounds each 
year—in addition to the 80,000 already 
in commerce. Yet, the agencies can only 
manage to test several hundred annu-
ally at a cost of roughly $1–2 million per 
compound.
The issue has become more urgent 
with a March 2008 report by John Ste-
phenson, director of Natural Resources 
and Environment with the Government 
Accountability Office (GAO). The report 
reviews the EPA’s efforts to control the 
risks of new and existing chemicals 
under the outdated Toxic Substances Control Act, unchanged since 1976, and 
finds those efforts lacking. Among other 
problems, the report notes that the EPA 
lacks the authority to require companies 
to safety test their own chemicals and 
criticizes the animal models as often 
inaccurate or unable to predict ultimate 
toxicity in humans.
For example, the gold standard of 
toxicology, called acute toxicity testing, 
is far from perfect. Typically, scientists 
give animals one dose of a test chemical, 
administered for not more than 24 hr, and 
then count the number that have died 14 
days later; that number is recorded and 
plotted as the lethal dose for 50% of the 
animals or LD50. The idea is to identify 
doses that cause no adverse effects 
versus those that cause life-threaten-
ing toxicity. Despite the time, cost, and 
potential waste of such testing practices, 
an estimated 35% of pharmaceutical 
compounds tested in animals histori-
cally have failed in human clinical trials 
because of toxicity problems. “Rodent 
models are imperfect instruments, at 
best, and very expensive,” says chemical 
biologist Christopher Austin, director of 
the Chemical Genomics Center (NCGC) 
at the National Institutes of Health (NIH) 
in Bethesda, MD. “Combined with the 
increasing public unease with using ani-
mals for toxicology, it was just obvious 
to a number of us that we should try a 
new way.”
On the public front, that way is a new 
piece of legislation, “The Kid Safe Chemi-
cals Act,” introduced on May 20 this year 
by US Senator Frank R. Lautenberg, a 
New Jersey Democrat, along with two 
other members of the US Congress. 
The legislation would require chemi-
cal manufacturers to provide health and 
safety information on everyday chemicals 
instead of presuming a substance is safe 
until proven dangerous.Cell 13From a research perspective, the 
attempt to procure that heath and safety 
information happened in 2005, when the 
newly formed NCGC joined forces with 
the National Human Genome Research 
Institute (NHGRI), the NTP/National Insti-
tute of Environmental Health Sciences 
(NIEHS), and the EPA. The NIH had 
established the NCGC in 2004 to pro-
vide academic investigators with a high-
throughput screening and chemical probe 
capacity previously available only in the 
pharmaceutical industry. With that capac-
ity in mind, the NHGRI/NTP/EPA col-
laborators were thrilled when the National 
Academy of Sciences (NAS) came out with 
a report about the future of toxicology 
(http://www.nap.edu/catalog.php?record_
id=11970). The NAS vision recognized the 
importance of new technologies, including 
high-throughput screening, in the field of 
toxicology and recommended the integra-
tion of so-called “toxicogenomics” into 
regulatory decision making. In response 
to the report, the NCGC-NTP-EPA tri-
umvirate published a memorandum of 
understanding (http://www.genome.gov/
Pages/ Newsroom/CurrentNewsReleases/ 
ntpncgcepamou121307FinalV2.pdf) in which 
they committed to implement the NAS 
vision. The EPA would provide chemicals 
for testing and computational expertise; 
the NTP would offer its knowledge of 
toxicology and a database of compounds; 
and, crucially, the NCGC would offer high-
throughput cell-based screening of new 
chemicals. The NAS report “gave a third-
party independent validation to exactly the 
approach our collaboration was taking,” 
says NCGC’s Austin.
Thus far, the collaboration has screened 
3000 chemicals in over 50 high-throughput 
cell-based screening assays. In a paper 
published earlier this year in Environmen-
tal Health Perspectives, the group estab-
lished “proof of principle.” They compared 4, August 22, 2008 ©2008 Elsevier Inc. 557
results using cells of the same type but 
derived from different species—for exam-
ple, kidney cells from rat and human. The 
key finding was what cell biologists have 
long known: a rodent is not a mini-human. 
For example, in a cell viability assay based 
upon the enzyme luciferase, coupled to 
ATP quantification, researchers found that 
the overall activity profiles of substances 
tested in human SH-SY5Y neuroblas-
toma cells differed markedly from those in 
mouse N2a neuroblastoma cells. In addi-
tion, the researchers found that test chemi-
cals often behave very differently in human 
cell types thought to be closely related to 
each other. Overall, 39 tested compounds 
showed significant differences depend-
ing on the species, with 34 having greater 
potency in rodent cells and 5 being more 
toxic to human cells. “This paper shows 
that we can generate reliable reproduc-
ible data based on high-throughput tech-
niques,” Austin says. “It also gives you a 
really tantalizing view of both the promise 
and complexity of our approach.”
The European Perspective
Meanwhile, European scientists and 
regulatory agencies are facing similar 
pressures to update their toxicity test-
ing guidelines. As with the situation in 
the US, one of the biggest incentives is 
cost. Animal tests in Europe consume 
roughly 3 billion euros per year, and it 
takes ~150,000 animals to test one new 
chemical to current regulatory guide-
lines. Added to that are the 30,000 exist-
ing commercial chemicals of which 86% 
lack full toxicology data. European sci-
entists have calculated that it would take 
67 million animals if regulators were to 
treat the 30,000 high-priority substances 
like new chemicals, with still another 
110,000 lower-priority chemicals possi-
bly to be tested in the future. Added to 
the enormous cost of using animals in 
toxicity testing is tough European Com-
mission (EC) legislation—the Seventh 
Amendment of the Cosmetics Directive 
(adopted in 2003)—which requires that 
by January 2009, no cosmetic can be 
sold in Europe if it or its ingredients have 
been tested in animals. (Substances 
tested before 2004 are exempt from the 
legislation. And some kinds of animal 
testing, including repeated dose toxicity, 
reproductive toxicity, and toxicokinetics, 
have until March 2013 before phase out.) 558 Cell 134, August 22, 2008 ©2008 Elsev“This is a marketing ban and a very pow-
erful one,” says Goldberg. “Because it 
affects companies that want to sell their 
products in Europe, the amendment has 
worldwide reach.”
Coupled with this is a new EC Regulation 
called REACh (Registration, Evaluation, 
Authorisation and Restriction of Chemical 
substances) that became effective June 
1, 2007. REACh mandates that manufac-
turers and importers gather information 
on the properties of their chemical sub-
stances and register this information in a 
central database run by a new European 
Chemicals Agency in Helsinki. Because 
there are an estimated 140,000 existing 
chemicals in Europe, the agency is now 
prioritizing, based on which substances 
are produced in the highest volumes. The 
top 30,000 will be evaluated for toxicity 
and results posted in a public database 
(http://echa.europa.eu/home_en.asp). 
Such regulatory urgency is spurring the 
development of alternatives to animal 
testing both in academic and commercial 
laboratories. 
To assist in these efforts, the Euro-
pean Union (EU) is now spending 25 
million euros each year to fund a mixed 
consortia of up to 30 partners, most 
from academia but some from large 
cosmetic, chemical, and pharmaceuti-
cal companies. In addition, there are 
some incentives to get more small/
medium enterprises involved. Once new 
cell-based in vitro assays are developed 
they are validated by the European Cen-
tre for Validation of Alternative Methods 
(ECVAM) in Ispra, Italy. ECVAM com-
pares each new in vitro assay devel-
oped with the standard animal model 
and makes sure that the new test is 
comparable or better. Similar organi-
zations exist elsewhere, including the 
Interagency Coordinating Committee 
on the Validation of Alternative Methods 
(ICCVAM) in the US and the Japanese 
Center for the Validation of Alternative 
Methods (JaCVAM) in Japan. As ethical, 
regulatory, and proprietary interests are 
now intersecting, the quest for in vitro 
alternatives has become a “win-win 
situation,” says Thomas Hartung, for-
mer head of ECVAM and current head 
of the EC’s Unit for Traceability, Risk 
and Vulnerability Assessment. “In the 
end, everybody wants to have validated 
alternative tests available,” he says. ier Inc.“Industry is coming up with procedures 
that we can use and they are very hap-
pily applying our assays that have been 
validated.”
But the validation process is lengthy 
(2–8 years), cumbersome, and costly 
(~$300,000 per test). And validation 
by ECVAM is not the last step. ECVAM 
must present its validated tests to OECD 
(Organization for Economic Coopera-
tion and Development). Although not an 
“organization” per se, the OECD offers a 
discussion forum for its 30 full member 
countries, including the US. The OECD 
in 1981 passed the Mutual Acceptance 
of Data Act, which states that all member 
states must accept ultimate OECD test 
guidelines. Thus, a substance tested 
in, say, France automatically complies 
with the standards of Austria. The result 
was a streamlined efficiency in toxicity 
testing because different countries did 
not have to perform duplicate testing 
in order to market products throughout 
Europe. But the law also caused a major 
setback because test guidelines decided 
30 years ago have become “frozen in 
time,” says Hartung. That’s because 
all OECD countries must agree to any 
change. For example, the controversial 
Draize Test developed in 1944—in which 
a test substance is applied to the eye or 
skin of an animal (usually an albino rab-
bit) and the level of irritation monitored—
is still performed today, albeit with some 
modifications and on reduced numbers 
of animals.
Given such constraints, ECVAM thus 
far has validated and approved at the 
OECD level only three in vitro cell-based 
assays (for skin corrosion and phototox-
icity) that fully replace animals for test-
ing. In the skin corrosion in vitro assay, 
scientists apply the test chemical to an 
“epidermis” in culture reconstructed 
from multiple layers of human keratino-
cytes under a functional layer of corneal 
cells. Next, researchers test cell viability 
at specified exposures to the chemical 
with the dye MTT. In another validated 
test, researchers create discs of rat skin 
and apply a test substance to the inner 
epithelium. Researchers then measure 
potential corrosiveness based on the 
skin’s resistance to an electrical current 
passed across the disc; they test pene-
tration of the chemical based on move-
ment of the dye sulforhodamine. Finally, 
scientists can measure phototoxicity 
with a test called 3T3 NRU PT, in which 
researchers expose a mouse fibroblast 
cell line to the chemical and compare 
cytotoxicity (as measured by the cell’s 
ability to take up a vital dye called neu-
tral red) with and without exposure to 
UVA under carefully defined conditions. 
Other cell-based assays have been 
accepted or are under discussion to 
either fully replace animals or reduce 
the number used.
Back to the Petri Dish
As these new in vitro tests feed into the 
alternative cell-based assay pipeline, they 
reveal a healthy growth in the basic sci-
ence of toxicology. Researchers are suc-
cessfully creating sophisticated tissue, 
cellular, and high-throughput assays, 
as well as computer modeling to mea-
sure and predict the effects of various 
substances on overall physiology. For 
example, researchers have been able to 
create and commercialize artificial human 
skin equivalents derived from cultured 
human cells. Researchers at MatTek in 
Ashland, MA have created models such 
as tracheal/bronchial epithelium and four 
types of vaginal tissues derived from 
human epithelial and dendritic cells. Sci-
entists at SkinEthic in Nice, France have 
created their EpiSkin model by culturing 
adult human keratinocytes (from plastic 
surgery donors) on a collagen base under 
conditions that allow the terminal differ-
entiation of cells and the reconstruction 
of a functional epidermis. Finally, inves-
tigators at Phenion in Duesseldorf, Ger-
many have developed a full thickness 
skin model based on biopsy material from 
healthy human donors. Researchers cul-
ture the mix of epidermal and dermal cells 
in a stable matrix that does not contract 
under physiological forces in order to 
cultivate a structure similar to the dermis 
and then overlay keratinocytes to form 
the epidermis.
According to Klaus Schroeder, head 
of development at Phenion, there is an 
enormous demand for these new cell-
based assays. For example, scientists currently use two primary in vitro assays 
to screen cosmetic ingredients: cultures 
of mammalian epidermal cells and a 
bacterial mutagenesis assay called the 
Ames test. Both produce a high number 
of false positives, says Schroeder. A pos-
itive result means the ingredient immedi-
ately has to be tested in whole animals. 
“There is a link missing between simple 
cell culture and the whole animal,” says 
Schroeder. “This link could be an artifi-
cial skin equivalent.”
Representatives from the cosmetic 
industry agree. They are faced with an 
enormous dilemma. How can they meet 
the 2009 and 2013 deadlines for EC leg-
islation while currently lacking the requi-
site in vitro alternatives? The answer is 
to band together. Cosmetic, toiletry, and 
perfume companies are now working 
through Colipa, a European Trade Asso-
ciation, to help ECVAM speed the vali-
dation of new in vitro tests. New assays 
are being developed everywhere—from 
academia, to start-up biotech compa-
nies, to in-house research laboratories 
at cosmetic giants such as tissue engi-
neering facilities built by L’Oreal in Lyon 
and Nice, France as well as in China. 
In 2006, a subsidiary of L’Oreal called 
EpiSkin acquired SkinEthic. In April 2007, 
ECVAM announced the validation of the 
SkinEthic epidermis-on-collagen assay 
as a full replacement method for chemi-
cal testing in animals. In addition, L’Oreal 
has partnered with an information tech-
nology start-up called Solidus in Troy, 
NJ. The partnership will explore using 
computer algorithms in conjunction with 
cell assays to both manage the informa-
tion load of high-throughput technolo-
gies and also simulate the toxicology 
dynamics of a whole animal in silico.
Beyond building tissue engineer-
ing resources and partnering with bio-
tech, perhaps the most striking shift in 
industry is the collaboration between 
the major players themselves, including 
L’Oreal, Proctor & Gamble, and Estee 
Lauder. The companies are actually put-
ting much of their toxicology tests and 
data on the table. “It is not a kind of race,” Cell 13says Patricia Pineau, Scientific Com-
munication Director, L’Oreal Research 
in Paris. “While the lack of competition 
seems bizarre for industry, we are really 
sharing.” The reason is that what the 
industry is swapping is not information 
about their products but rather informa-
tion about the testing of their products. 
What cosmetic company wants to spend 
money developing toxicology tests when 
the budget could be spent on new prod-
uct innovation?
Despite this push, however, the regu-
latory framework remains conservative. 
“We are still doing the same toxicology 
animal experiments from 40 years ago,” 
Hartung says. “There is a tremendous 
disconnect between the basic science 
and the regulation. There is no other area 
in science where this has happened so 
dramatically.” Still, toxicology is shift-
ing from an observational enterprise 
(how many animals died or developed 
tumors) to a more predictive science 
(what fingerprint of cellular responses 
can tell us that this substance likely 
causes kidney failure in a human). That 
is exactly what the British scientists 
W.M.S. Russell and R.L. Burch sought 
when they developed their “3 R’s rule” 
(reducing, refining, and replacing) for 
chemical testing in animals nearly half 
a century ago. Although in vitro cell-
based alternatives can reduce the num-
ber of animals being tested, can help to 
refine the methodologies used, and ulti-
mately will replace animal models, what 
remains to be seen is not whether this 
will happen—but how. Clearly research-
ers working on the basic science of tox-
icology can anticipate big changes for 
their field, with those adept in veterinary 
science joining others with expertise in 
cell culture, robotics, and bioinformat-
ics. “Basic researchers should think 
about the processes that they study 
from a toxicological—not a beneficial—
perspective,” says Austin. “Think about 
what perturbs a process in the cell and 
how that could be adapted for a high-
throughput screen. And then, when 
you’ve got it, call me.”
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